SOGROYA is indicated for the:

•

Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH).

•

Replacement of endogenous GH in adults with growth hormone deficiency (GHD).

 

SOGROYA is a clear to slightly opalescent and colorless to slightly yellow solution available as follows:

•

Injection: 5 mg/1.5 mL (3.3 mg/mL) in a single-patient-use prefilled pen (teal)

•

Injection: 10 mg/1.5 mL (6.7 mg/mL) in a single-patient-use prefilled pen (yellow)

•

Injection: 15 mg/1.5 mL (10 mg/mL) in a single-patient-use prefilled pen (red)

SOGROYA is contraindicated in patients with:

•

Acute critical illness after open-heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure because of the risk of increased mortality with use of pharmacologic doses of SOGROYA [see Warnings and Precautions (5.1)].

•

Hypersensitivity to SOGROYA or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin [see Warnings and Precautions (5.2)].

•

Pediatric patients with closed epiphyses.

•

Active malignancy [see Warnings and Precautions (5.3)].

•

Active proliferative or severe non-proliferative diabetic retinopathy.

•

Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to risk of sudden death [see Warnings and Precautions (5.13)].

 

The following clinically significant adverse drug reactions are described elsewhere in the labeling:

•

Increased mortality in patients with acute critical illness [see Warnings and Precautions (5.1)]

•

Severe hypersensitivity [see Warnings and Precautions (5.2)]

•

Increased risk of neoplasms [see Warnings and Precautions (5.3)]

•

Glucose intolerance and diabetes mellitus [see Warnings and Precautions (5.4)]

•

Intracranial hypertension [see Warnings and Precautions (5.5)]

•

Fluid retention [see Warnings and Precautions (5.6)]

•

Hypoadrenalism [see Warnings and Precautions (5.7)]

•

Hypothyroidism [see Warnings and Precautions (5.8)]

•

Slipped capital femoral epiphysis in pediatric patients [see Warnings and Precautions (5.9)]

•

Progression of preexisting scoliosis in pediatric patients [see Warnings and Precautions (5.10)]

•

Pancreatitis [see Warnings and Precautions (5.11)]

•

Lipohypertrophy/Lipoatrophy [see Warnings and Precautions (5.12)]

•

Sudden death in pediatric patients with Prader-Willi syndrome [see Warnings and Precautions (5.13)]

Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SOGROYA and instructions for preventing or managing them.

Table 4. Clinically Important Drug Interactions with SOGROYA

 

 

Acute overdosage could lead initially to hypoglycemia and subsequently to hyperglycemia. Overdose with SOGROYA is likely to cause fluid retention. Long-term overdosage could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess endogenous growth hormone.

Somapacitan-beco is a human growth hormone (hGH) analog with a single substitution in the amino acid backbone (L101C) to which an albumin-binding moiety has been attached. The albumin-binding moiety (side-chain) consists of an albumin binder and a hydrophilic spacer attached to position 101 of the protein. The protein part consists of 191 amino acids. Somapacitan-beco is produced in Escherichia coli by recombinant DNA technology. The molecular formula (including the albumin-binding moiety) is C1038H1609N273O319S9 and the molecular weight is 23305.10 g/mol, of which the albumin-binding moiety is 1191.39 g/mol.

Structural Formula:

SOGROYA (somapacitan-beco) injection is supplied as a sterile, clear to slightly opalescent and colorless to slightly yellow solution for subcutaneous use in a single-patient-use prefilled pen with a deliverable volume of 1.5 mL.

Each mL of SOGROYA 5 mg/1.5 mL prefilled pen contains 3.3 mg of somapacitan-beco, histidine (0.68 mg), mannitol (44 mg), phenol (4 mg), poloxamer 188 (1 mg), and Water for Injection, USP. The pH is approximately 6.8. Hydrochloric acid and sodium hydroxide may be added to adjust the pH.

Each mL of SOGROYA 10 mg/1.5 mL prefilled pen contains 6.7 mg of somapacitan-beco, histidine (0.68 mg), mannitol (44 mg), phenol (4 mg), poloxamer 188 (1 mg), and Water for Injection, USP. The pH is approximately 6.8. Hydrochloric acid and sodium hydroxide may be added to adjust the pH.

Each mL of SOGROYA 15 mg/1.5 mL prefilled pen contains 10 mg of somapacitan-beco, histidine (0.68 mg), mannitol (44 mg), phenol (4 mg), poloxamer 188 (1 mg), and Water for Injection, USP. The pH is approximately 6.8. Hydrochloric acid and sodium hydroxide may be added to adjust the pH.

 

 

How Supplied

SOGROYA (somapacitan-beco) injection is a clear to slightly opalescent and colorless to slightly yellow solution available as one 1.5 mL single-patient-use prefilled pen per carton:

•

SOGROYA 5 mg/1.5 mL (3.3 mg/mL) pen (teal) NDC 0169-2035-11

•

SOGROYA 10 mg/1.5 mL (6.7 mg/mL) pen (yellow) NDC 0169-2030-11

•

SOGROYA 15 mg/1.5 mL (10 mg/mL) pen (red) NDC 0169-2037-11

Storage and Handling

Before and during use: Store in a refrigerator at 36°F to 46°F (2°C to 8°C) with the cap on and in the original carton to protect from light. Do not freeze. Do not use SOGROYA if it has been frozen. Discard prefilled pen if kept above 86°F (30°C). Avoid direct or excessive heat. Avoid sunlight. Refer to storage conditions for SOGROYA (Table 8).

Write the date of first use in the space provided on the carton.

Always remove and safely discard the needle after each injection and store the SOGROYA prefilled pen without an injection needle attached. Always use a new needle for each injection to prevent contamination.

Table 8. Storage conditions for SOGROYA

 

*The total time allowed at room temperature (up to 77°F [25°C]) is 72 hours (3 days) regardless of whether the product is in-use (opened) or before first use (unopened). Must discard if kept above 86°F (30°C).

Advise patients and/or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

•

Advise patients and/or caregivers to administer SOGROYA once weekly.

•

Hypersensitivity - Advise patients and/or caregivers that severe and/or serious systemic hypersensitivity reactions (anaphylaxis and angioedema) have been reported, and to seek prompt medical attention should an allergic reaction occur [see Warnings and Precautions (5.2)].

•

Neoplasms – Advise patients to report marked changes in skin pigmentation or changes in the appearance of preexisting nevi.

•

Glucose Intolerance/Diabetes Mellitus – Advise patients that new onset pre- /diabetes mellitus or exacerbation of preexisting diabetes mellitus can occur and monitoring of blood glucose during treatment with SOGROYA may be needed.

•

Intracranial Hypertension - Advise patients to report to their healthcare provider any visual changes, headache, and nausea and/or vomiting.

•

Fluid Retention - Advise patients that fluid retention during SOGROYA replacement therapy may frequently occur. Inform patients of the clinical manifestations of fluid retention (e.g. edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paresthesia) and to report to their healthcare provider any of these signs or symptoms occur during treatment with SOGROYA.

•

Hypoadrenalism - Advise patients who have or who are at risk for corticotropin deficiency that hypoadrenalism may develop and to report to their healthcare provider if they experience hyperpigmentation, extreme fatigue, dizziness, weakness, or weight loss.

•

Hypothyroidism - Advise patients/caregivers that undiagnosed/untreated hypothyroidism may prevent an optimal response to SOGROYA. Advise patients/caregivers they may require periodic thyroid function tests.

•

Pancreatitis - Advise patients that pancreatitis may develop and to report to their healthcare provider any new onset abdominal pain.

•

Lipohypertrophy/ Lipoatrophy – Advise patients that lipohypertrophy or lipoatrophy can occur if SOGROYA is administered subcutaneously at the same site over a long period of time. Advise patients to rotate injection sites when administering SOGROYA to reduce this risk.

Novo Nordisk® is a registered trademark of Novo Nordisk A/S.

SOGROYA® is a registered trademark of Novo Nordisk Health Care AG.

© 2002-2023 Novo Nordisk Health Care AG

PATENT INFORMATION: http://novonordisk-us.com/products/product-patents.html

For information contact:

Novo Nordisk Inc.

800 Scudders Mill Road

Plainsboro, New Jersey 08536

1-888-668-6444

Manufactured by:

Novo Nordisk Inc.

Plainsboro, NJ 08536

U.S. License No. 1261

SOGROYA® (suh-GROY-uh)

(somapacitan-beco) injection, for subcutaneous use

What is SOGROYA?

•

SOGROYA is a prescription medicine that contains human growth hormone, the same growth hormone made by the human body.

•

SOGROYA is given by injection under the skin (subcutaneous) and is used to treat adults and children 2.5 years and older who do not make enough growth hormone.

Do not use SOGROYA if:

•

you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing (respiratory) problems.

•

you have cancer or other tumors.

•

you are allergic to somapacitan-beco or any of the ingredients in SOGROYA. See the end of this Patient Information leaflet for a complete list of ingredients in SOGROYA.

•

your healthcare provider tells you that you have certain types of eye problems caused by diabetes (diabetic retinopathy).

•

you are a child with closed bone growth plates.

•

you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stop breathing during sleep).

Before taking SOGROYA, tell your healthcare provider about all of your medical conditions, including if you:

•

have had heart or stomach surgery, trauma or serious breathing (respiratory) problems.

•

have had cancer or any tumor.

•

have diabetes.

•

have adrenal gland problems.

•

are taking replacement therapy with glucocorticoids.

•

have thyroid gland problems.

•

have liver problems.

•

are a child with a history of worsening of curvature of the spine (scoliosis).

•

are pregnant or plan to become pregnant. It is not known if SOGROYA will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.

•

are breastfeeding or plan to breastfeed. It is not known if SOGROYA passes into your breast milk. You and your healthcare provider should decide if you will take SOGROYA while you breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOGROYA may affect how other medicines work, and other medicines may affect how SOGROYA works.

How should I use SOGROYA?

•

Read the detailed Instructions for Use that come with SOGROYA.

•

SOGROYA comes in 3 strengths: 5 mg/1.5 mL (3.3 mg/mL) pen, 10 mg/1.5 mL (6.7 mg/mL) pen, and 15 mg/1.5 mL (10 mg/mL) pen. Your healthcare provider will prescribe the dose that is right for you.

•

Your healthcare provider will show you how to inject SOGROYA.

•

Use SOGROYA exactly as your healthcare provider tells you to.

•

Use SOGROYA 1 time each week.

•

If you miss a dose of SOGROYA, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day.

•

If more than 3 days (72 hours) have passed, skip the missed dose and take your next dose on the regularly scheduled dosing day.

•

SOGROYA pens are for use by 1 person only.

•

Do not share your SOGROYA pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them.

What are the possible side effects of SOGROYA?

SOGROYA may cause serious side effects, including:

•

high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing (respiratory) problems.

•

increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin.

•

new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with SOGROYA.

•

increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider.

•

serious allergic reactions. Get medical help right away if you or your child have the following symptoms:

•

your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention.

•

decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child has darkening of the skin, severe fatigue, dizziness, weakness, or weight loss.

•

decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well SOGROYA works. The healthcare provider will do blood tests to check your or your child’s thyroid hormone levels.

•

severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain.

•

loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject SOGROYA.

•

worsening of curvature of the spine in children (scoliosis).

•

hip and knee pain or a limp in children (slipped capital femoral epiphysis).

•

high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea. See “Do not use SOGROYA if”.

•

increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. Your or your child’s healthcare provider will do blood tests to check this.

The most common side effects of SOGROYA in children include:

The most common side effects of SOGROYA in adults include:

These are not all the possible side effects of SOGROYA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Novo Nordisk at 1-888-668-6444.

How should I store SOGROYA?

•

Before you use SOGROYA pens for the first time:

o

Store your new, unused SOGROYA pen in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).

o

Store your new, unused SOGROYA pen with the cap on and keep it in the original carton.

o

Do not freeze SOGROYA.

o

Keep SOGROYA away from direct heat and light.

o

Do not use SOGROYA that has been frozen or in temperatures warmer than 86ºF (30ºC).

o

Do not use SOGROYA after the expiration date printed on the carton and the pen.

•

After you use SOGROYA pens and there is still medicine left:

o

Store remaining SOGROYA in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC) and use within 6 weeks.

o

Store your in-use SOGROYA pen with the cap on and keep it in the original carton.

•

If needed, unused and in-use SOGROYA pens can be stored out of the refrigerator. SOGROYA pens can be stored at room temperature no warmer than 77ºF (25ºC) for up to 3 days (72 hours) and then returned to the refrigerator.

Keep SOGROYA and all medicines out of the reach of children.

General information about the safe and effective use of SOGROYA.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SOGROYA for a condition for which it was not prescribed. Do not give SOGROYA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SOGROYA that is written for health professionals.

What are the ingredients in SOGROYA?

Active ingredient: somapacitan-beco

Inactive ingredients: histidine, mannitol, phenol, poloxamer 188, Water for Injection, and hydrochloric acid and sodium hydroxide (as needed)

Manufactured by: Novo Nordisk Inc., Plainsboro, NJ 08536

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 04/2023

Supplies you will need:

•

SOGROYA prefilled Pen

•

new injection needle. SOGROYA prefilled Pen is designed to be used with all Novo Nordisk disposable needles up to a length of 8 mm.

•

sharps disposal container. See Step 5 for information on how to throw away (dispose of) used needles and Pens.

•

alcohol pad

•

gauze pad

How to use your SOGROYA Pen

5 steps you should follow for a SOGROYA injection:

Step 1: Prepare your SOGROYA Pen

Step 2: Check the SOGROYA flow with each new Pen

Step 3: Select your dose

Step 4: Inject your dose

Step 5: After your injection

For further information about your Pen see: Frequently Asked Questions and Important information

Important information

Pay special attention to these notes as they are important for safe use of the Pen.

Additional information

SOGROYA is a prefilled growth hormone Pen. It contains 5 mg of somapacitan-beco and delivers doses from 0.025 mg to 2.0 mg, in increments of 0.025 mg. SOGROYA is for use under the skin only (subcutaneous) for injection 1 time each week.

Do not share your SOGROYA Pen and needles with another person. You may give another person an infection or get an infection from them.

Do not use your Pen without proper training from your healthcare provider. Make sure that you are confident in giving an injection with the Pen before you start your treatment. If you are blind or have poor eyesight and cannot read the dose counter on the Pen, do not use this Pen without help. Get help from a person with good eyesight who is trained to use the Pen.

Step 1. Prepare your SOGROYA Pen

•

Wash your hands with soap and water.

•

Check the name, strength, and colored label on your Pen to make sure that it contains SOGROYA in the right strength.

•

Pull off the Pen cap.

•

Turn the Pen upside down 1 or 2 times to check that the SOGROYA in your Pen is clear to almost clear and colorless to slightly yellow (See Figure A). If SOGROYA looks cloudy or you see particles, do not use the Pen.

•

When you are ready to give your injection, get a new disposable needle, and remove the paper tab.

•

Push the needle straight onto the Pen. Turn the needle clockwise until it is on tight (See Figure B).

Make sure the right pen is used. Especially if you use more than one type of injection medicine. Using the wrong medicine could be harmful to your health.

Always use a new needle for each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

•

Pull off the outer needle cap and throw it away (dispose of) (See Figure C).

•

Pull off the inner needle cap and throw it away (dispose of) (See Figure D).

A drop of SOGROYA may appear at the needle tip. This is normal, but you must still check the SOGROYA flow with each new Pen (See Step 2).

Never use a bent or damaged needle.

Step 2. Check the SOGROYA flow with each new Pen

If your Pen is already in use, go to Step 3.

•

Before using a new Pen, check the SOGROYA flow to make sure the growth hormone can flow through the Pen and needle.

•

Turn the dose selector clockwise 1 marking on the dose counter to select 0.025 mg. You may hear a faint “click” when you turn the dose selector (See Figure E).

•

1 marking on the dose counter equals 0.025 mg (See Figure F).

•

Hold the Pen with the needle pointing up. Press and hold in the dose button until the dose counter returns to “0”. The “0” must line up with the dose pointer (See Figure G).

•

Check that a drop of SOGROYA appears at the needle tip (See Figure H).

If no SOGROYA appears, repeat Step 2 up to 6 times.

If you still do not see a drop of SOGROYA, change the needle:

•

Carefully remove the needle from the Pen by turning the needle counterclockwise. Place the needle in a sharps disposal container immediately (See Step 5).

•

Repeat Step 2 again.

Do not use the Pen if a drop of SOGROYA still does not appear after changing the needle and repeating Step 2. Call Novo Nordisk at 1-888-668-6444 for help.

Step 3. Select your dose

•

To start, check that the dose pointer is set at “0”.

•

Turn the dose selector clockwise to select the dose you need (See Figure I). When you have selected your dose, you can go to Step 4.

If there is not enough SOGROYA left to select a full dose, see Frequently Asked Questions.

The dose counter shows the dose in “mg” (See Figure J and Figure K). Always use the dose counter to select the exact dose. Do not use the “click” sounds you hear when you turn the dose selector to select your dose. Only the dose pointer on the dose counter will show the exact dose selected.

If you select the wrong dose, you can turn the dose selector clockwise or counterclockwise to the correct dose (See Figure L).

The Pen “clicks” sound and feel differently when the dose selector is turned clockwise, counterclockwise, or if you forcefully move it past the number of “mg” left in the Pen.

Step 4. Inject your dose

•

Select the injection site.

•

SOGROYA can be injected under the skin (subcutaneously) of your stomach area (abdomen) or upper legs (thighs) as instructed by your healthcare provider (See Figure M). Change the injection site every week.

•

Wipe the injection site with an alcohol pad and let the area dry.

•

Insert the needle into your skin as your healthcare provider has shown you (See Figure N).

•

Make sure you can see the dose counter. Do not cover it with your fingers. This could block the injection.

•

Press and hold down the dose button until the dose counter shows “0” (See Figure O). The “0” must line up with the dose pointer. You may then hear or feel a “click”.

•

Continue to hold down the dose button with the needle in your skin.

If “0” does not appear in the dose counter after continuously pressing the dose button, your needle may be blocked or damaged. See Frequently Asked Questions.

•

Keep holding down the dose button with the needle in your skin and slowly count to 6 to make sure that the full dose has been delivered (See Figure P).

•

Carefully remove the needle from your skin (See Figure Q). If blood appears at the injection site, press lightly with a gauze pad. Do not rub the area.

You may see a drop of SOGROYA at the needle tip after injecting. This is normal and does not affect your dose.

Step 5. After your injection

•

Carefully remove the needle from the Pen by turning the needle counterclockwise (See Figure R).

•

Place the needle in an FDA-cleared sharps disposal container immediately to reduce the risk of a needle stick (See Figure R).

Always throw away (dispose of) the needle after each injection.

For further information about safe sharps disposal, see Frequently Asked Questions.

•

Put the Pen cap on your Pen after each use to protect SOGROYA from direct light (See Figure S). See “How should I store my SOGROYA Pen?”.

Do not try to put the needle cap back on. You may stick yourself with the needle.

Always remove the needle from your Pen immediately after each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

How should I store my SOGROYA Pen?

Before you use SOGROYA Pen for the first time:

•

Store your new, unused SOGROYA Pen in a refrigerator between 36°F to 46°F (2°C to 8°C).

•

Store your new, unused SOGROYA Pen with the cap on and in the original carton.

•

Do not freeze SOGROYA.

•

When stored in the refrigerator, do not store the SOGROYA Pen directly next to the cooling element.

•

Keep SOGROYA away from direct heat and light.

•

Do not use SOGROYA if it has been frozen or in temperatures warmer than 86ºF (30°C).

•

Do not use SOGROYA after the expiration date printed on the carton and the Pen.

After you use SOGROYA Pen and there is still medicine left:

•

Store remaining SOGROYA in the refrigerator between 36°F to 46°F (2°C to 8°C) and use within 6 weeks.

•

Store your in-use SOGROYA Pen with the cap on and keep it in the original carton.

Do not store SOGROYA Pen with the needle attached.

If needed, unused and in-use SOGROYA pens can be stored out of the refrigerator. SOGROYA pens can be stored at room temperature no warmer than 77ºF (25ºC) for up to 3 days (72 hours) and then returned to the refrigerator. Throw away (dispose of) SOGROYA if it has been stored above 77°F (25°C) for more than 3 days (72 hours) or in temperatures warmer than 86°F (30°C).

Always keep your SOGROYA Pen and needles out of reach of others, especially children.

Frequently Asked Questions

How do I see how much SOGROYA is left in my Pen?

The Pen scale shows you approximately how much SOGROYA is left in your Pen (See Figure T).

To see how much SOGROYA is left in your Pen, use the dose counter:

Turn the dose selector clockwise until the dose counter stops. The dose pointer will line up with the number of “mg” left in the Pen. You can select a maximum dose of 2.0 mg. If the dose counter stops with the dose pointer lined up with “2”, at least 2.0 mg are left in your Pen.

If the dose counter stops with the dose pointer lined up with “1.7”, only 1.7 mg are left in your Pen (See Figure U).

What if I need a larger dose than what is left in my Pen?

It is not possible to select a larger dose on the dose counter than the number of “mg” left in your Pen. If you need more SOGROYA than you have left in your Pen, you can use a new Pen or split your dose between your current Pen and a new Pen. Only split your dose if you have been trained or advised by your healthcare provider on how to do this. You may find it helpful to use a calculator to plan the doses as instructed by your healthcare provider.

Be very careful to calculate your split dose correctly so that you do not give the wrong dose. If you are not sure how to split your dose using 2 Pens, then select and inject the dose you need with a new Pen.

What if no SOGROYA appears when I check the flow?

A. Your needle may be blocked or damaged, if no SOGROYA appears at the needle tip. Remove the needle as described in Step 5 and repeat Step 1 and Step 2.

B. Your Pen may be defective, if SOGROYA still does not appear after changing the needle. Do not use the Pen. Contact Novo Nordisk at 1-888-668-6444.

What if “0” does not appear after completing my injection?

The needle may be blocked or damaged, and you have not received any SOGROYA, even though the dose counter has moved from the dose that you have set. Remove the needle as described in Step 5 and repeat Step 1 to Step 4.

How should I take care of my Pen?

Be careful not to drop your Pen or knock it against hard surfaces. Do not expose your Pen to dust, dirt, liquid, or direct light. See “How should I store SOGROYA?” Do not try to refill your Pen, it is prefilled.

What if I drop my Pen?

If you drop your Pen or think that something is wrong with it, attach a new disposable needle and check the SOGROYA flow before you inject (See Step 1 and Step 2). Do not try to repair your Pen or pull it apart.

How do I clean my Pen?

Do not wash, soak, or lubricate your Pen. If necessary, clean it with mild detergent on a moistened cloth.

Frequently Asked Questions

How do I throw away (dispose of) used SOGROYA needles and Pens?

Put your used needles and Pens in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and Pens in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:

•

made of a heavy-duty plastic,

•

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

•

upright and stable during use,

•

leak-resistant, and

•

properly labeled to warn of hazardous waste inside the container.

When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should dispose of used needles and Pens. For more information about safe sharps disposal, and for specific information about safe sharps disposal in the state that you live in, go to the FDA’s website at:

http://www.fda.gov/safesharpsdisposal.

Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Important information

•

Caregivers must be very careful when handling needles to reduce the risk of needle sticks and infection.

www.sogroya.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

PATENT Information: http://novonordisk-us.com/products/product-patents.html

SOGROYA® is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk® is a registered trademark of Novo Nordisk A/S.

© 2004-2023 Novo Nordisk Health Care AG

For further information contact:

Novo Nordisk Inc.

800 Scudders Mill Road

Plainsboro, NJ 08536, USA

1-888-668-6444

Sogroya.com

Manufactured by:

Novo Nordisk Inc.

Plainsboro, NJ 08536

U.S. License No. 1261

Issued: 10/2021

Version: 1

Supplies you will need:

•

SOGROYA prefilled Pen

•

new injection needle. SOGROYA prefilled Pen is designed to be used with all Novo Nordisk disposable needles up to a length of 8 mm.

•

sharps disposal container. See Step 5 for information on how to throw away (dispose of) used needles and Pens.

•

alcohol pad

•

gauze pad

How to use your SOGROYA Pen

5 steps you should follow for a SOGROYA injection:

Step 1: Prepare your SOGROYA Pen

Step 2: Check the SOGROYA flow with each new Pen

Step 3: Select your dose

Step 4: Inject your dose

Step 5: After your injection

For further information about your Pen see: Frequently Asked Questions and Important information

Important information

Pay special attention to these notes as they are important for safe use of the Pen.

Additional information

SOGROYA is a prefilled growth hormone Pen. It contains 10 mg of somapacitan-beco and delivers doses from 0.05 mg to 4.0 mg, in increments of 0.05 mg. SOGROYA is for use under the skin only (subcutaneous) for injection 1 time each week.

Do not share your SOGROYA Pen and needles with another person. You may give another person an infection or get an infection from them.

Do not use your Pen without proper training from your healthcare provider. Make sure that you are confident in giving an injection with the Pen before you start your treatment. If you are blind or have poor eyesight and cannot read the dose counter on the Pen, do not use this Pen without help. Get help from a person with good eyesight who is trained to use the Pen.

Step 1. Prepare your SOGROYA Pen

•

Wash your hands with soap and water.

•

Check the name, strength, and colored label on your Pen to make sure that it contains SOGROYA in the right strength.

•

Pull off the Pen cap.

•

Turn the Pen upside down 1 or 2 times to check that the SOGROYA in your Pen is clear to almost clear and colorless to slightly yellow (See Figure A). If SOGROYA looks cloudy or you see particles, do not use the Pen.

•

When you are ready to give your injection, get a new disposable needle, and remove the paper tab.

•

Push the needle straight onto the Pen. Turn the needle clockwise until it is on tight (See Figure B).

Make sure the right pen is used. Especially if you use more than one type of injection medicine. Using the wrong medicine could be harmful to your health.

Always use a new needle for each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

•

Pull off the outer needle cap and throw it away (dispose of) (See Figure C).

•

Pull off the inner needle cap and throw it away (dispose of) (See Figure D).

A drop of SOGROYA may appear at the needle tip. This is normal, but you must still check the SOGROYA flow with each new Pen (See Step 2).

Never use a bent or damaged needle.

Step 2. Check the SOGROYA flow with each new Pen

If your Pen is already in use, go to Step 3.

•

Before using a new Pen, check the SOGROYA flow to make sure the growth hormone can flow through the Pen and needle.

•

Turn the dose selector clockwise 1 marking on the dose counter to select 0.05 mg. You may hear a faint “click” when you turn the dose selector (See Figure E).

•

1 marking on the dose counter equals 0.05 mg (See Figure F).

•

Hold the Pen with the needle pointing up. Press and hold in the dose button until the dose counter returns to “0”. The “0” must line up with the dose pointer (See Figure G).

•

Check that a drop of SOGROYA appears at the needle tip (See Figure H).

If no SOGROYA appears, repeat Step 2 up to 6 times.

If you still do not see a drop of SOGROYA, change the needle:

•

Carefully remove the needle from the Pen by turning the needle counterclockwise. Place the needle in a sharps disposal container immediately (See Step 5).

•

Repeat Step 2 again.

Do not use the Pen if a drop of SOGROYA still does not appear after changing the needle and repeating Step 2. Call Novo Nordisk at 1-888-668-6444 for help.

Step 3. Select your dose

•

To start, check that the dose pointer is set at “0”.

•

Turn the dose selector clockwise to select the dose you need (See Figure I). When you have selected your dose, you can go to Step 4.

If there is not enough SOGROYA left to select a full dose, see Frequently Asked Questions.

The dose counter shows the dose in “mg” (See Figure J and Figure K). Always use the dose counter to select the exact dose. Do not use the “click” sounds you hear when you turn the dose selector to select your dose. Only the dose pointer on the dose counter will show the exact dose selected.

If you select the wrong dose, you can turn the dose selector clockwise or counterclockwise to the correct dose (See Figure L).

The Pen “clicks” sound and feel differently when the dose selector is turned clockwise, counterclockwise, or if you forcefully move it past the number of “mg” left in the Pen.

Step 4. Inject your dose

•

Select the injection site.

•

SOGROYA can be injected under the skin (subcutaneously) of your stomach area (abdomen) or upper legs (thighs) as instructed by your healthcare provider (See Figure M). Change the injection site every week.

•

Wipe the injection site with an alcohol pad and let the area dry.

•

Insert the needle into your skin as your healthcare provider has shown you (See Figure N).

•

Make sure you can see the dose counter. Do not cover it with your fingers. This could block the injection.

•

Press and hold down the dose button until the dose counter shows “0” (See Figure O). The “0” must line up with the dose pointer. You may then hear or feel a “click”.

•

Continue to hold down the dose button with the needle in your skin.

If “0” does not appear in the dose counter after continuously pressing the dose button, your needle may be blocked or damaged. See Frequently Asked Questions.

•

Keep holding down the dose button with the needle in your skin and slowly count to 6 to make sure that the full dose has been delivered (See Figure P).

•

Carefully remove the needle from your skin (See Figure Q). If blood appears at the injection site, press lightly with a gauze pad. Do not rub the area.

You may see a drop of SOGROYA at the needle tip after injecting. This is normal and does not affect your dose.

Step 5. After your injection

•

Carefully remove the needle from the Pen by turning the needle counterclockwise (See Figure R).

•

Place the needle in an FDA-cleared sharps disposal container immediately to reduce the risk of a needle stick (See Figure R).

Always throw away (dispose of) the needle after each injection.

For further information about safe sharps disposal, see Frequently Asked Questions.

•

Put the Pen cap on your Pen after each use to protect SOGROYA from direct light (See Figure S). See “How should I store my SOGROYA Pen?”.

Do not try to put the needle cap back on. You may stick yourself with the needle.

Always remove the needle from your Pen immediately after each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

How should I store my SOGROYA Pen?

Before you use SOGROYA Pen for the first time:

•

Store your new, unused SOGROYA Pen in a refrigerator between 36°F to 46°F (2°C to 8°C).

•

Store your new, unused SOGROYA Pen with the cap on and in the original carton.

•

Do not freeze SOGROYA.

•

When stored in the refrigerator, do not store the SOGROYA Pen directly next to the cooling element.

•

Keep SOGROYA away from direct heat and light.

•

Do not use SOGROYA if it has been frozen or in temperatures warmer than 86ºF (30°C).

•

Do not use SOGROYA after the expiration date printed on the carton and the Pen.

After you use SOGROYA Pen and there is still medicine left:

•

Store remaining SOGROYA in the refrigerator between 36°F to 46°F (2°C to 8°C) and use within 6 weeks.

•

Store your in-use SOGROYA Pen with the cap on and keep it in the original carton.

Do not store SOGROYA Pen with the needle attached.

If needed, unused and in-use SOGROYA pens can be stored out of the refrigerator. SOGROYA pens can be stored at room temperature no warmer than 77ºF (25ºC) for up to 3 days (72 hours) and then returned to the refrigerator. Throw away (dispose of) SOGROYA if it has been stored above 77°F (25°C) for more than 3 days (72 hours) or in temperatures warmer than 86°F (30°C).

Always keep your SOGROYA Pen and needles out of reach of others, especially children.

Frequently Asked Questions

How do I see how much SOGROYA is left in my Pen?

The Pen scale shows you approximately how much SOGROYA is left in your Pen (See Figure T).

To see how much SOGROYA is left in your Pen, use the dose counter:

Turn the dose selector clockwise until the dose counter stops. The dose pointer will line up with the number of “mg” left in the Pen. You can select a maximum dose of 4.0 mg. If the dose counter stops with the dose pointer lined up with “4”, at least 4.0 mg are left in your Pen.

If the dose counter stops with the dose pointer lined up with “2.8”, only 2.8 mg are left in your Pen (See Figure U).

What if I need a larger dose than what is left in my Pen?

It is not possible to select a larger dose on the dose counter than the number of “mg” left in your Pen. If you need more SOGROYA than you have left in your Pen, you can use a new Pen or split your dose between your current Pen and a new Pen. Only split your dose if you have been trained or advised by your healthcare provider on how to do this. You may find it helpful to use a calculator to plan the doses as instructed by your healthcare provider.

Be very careful to calculate your split dose correctly so that you do not give the wrong dose. If you are not sure how to split your dose using 2 Pens, then select and inject the dose you need with a new Pen.

What if no SOGROYA appears when I check the flow?

A. Your needle may be blocked or damaged, if no SOGROYA appears at the needle tip. Remove the needle as described in Step 5 and repeat Step 1 and Step 2.

B. Your Pen may be defective, if SOGROYA still does not appear after changing the needle. Do not use the Pen. Contact Novo Nordisk at 1-888-668-6444.

What if “0” does not appear after completing my injection?

The needle may be blocked or damaged, and you have not received any SOGROYA, even though the dose counter has moved from the dose that you have set. Remove the needle as described in Step 5 and repeat Step 1 to Step 4.

How should I take care of my Pen?

Be careful not to drop your Pen or knock it against hard surfaces. Do not expose your Pen to dust, dirt, liquid, or direct light. See “How should I store SOGROYA?” Do not try to refill your Pen, it is prefilled.

What if I drop my Pen?

If you drop your Pen or think that something is wrong with it, attach a new disposable needle and check the SOGROYA flow before you inject (See Step 1 and Step 2). Do not try to repair your Pen or pull it apart.

How do I clean my Pen?

Do not wash, soak, or lubricate your Pen. If necessary, clean it with mild detergent on a moistened cloth.

Frequently Asked Questions

How do I throw away (dispose of) used SOGROYA needles and Pens?

Put your used needles and Pens in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and Pens in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:

•

made of a heavy-duty plastic,

•

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

•

upright and stable during use,

•

leak-resistant, and

•

properly labeled to warn of hazardous waste inside the container.

When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should dispose of used needles and Pens. For more information about safe sharps disposal, and for specific information about safe sharps disposal in the state that you live in, go to the FDA’s website at:

http://www.fda.gov/safesharpsdisposal.

Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Important information

•

Caregivers must be very careful when handling needles to reduce the risk of needle sticks and infection.

www.sogroya.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

PATENT Information: http://novonordisk-us.com/products/product-patents.html

SOGROYA® is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk® is a registered trademark of Novo Nordisk A/S.

© 2004-2023 Novo Nordisk Health Care AG

For further information contact:

Novo Nordisk Inc.

800 Scudders Mill Road

Plainsboro, NJ 08536, USA

1-888-668-6444

Sogroya.com

Manufactured by:

Novo Nordisk Inc.

Plainsboro, NJ 08536

U.S. License No. 1261

Revised: 10/2021

Version: 2

Supplies you will need:

•

SOGROYA prefilled Pen

•

new injection needle. SOGROYA prefilled Pen is designed to be used with all Novo Nordisk disposable needles up to a length of 8 mm.

•

sharps disposal container. See Step 5 for information on how to throw away (dispose of) used needles and Pens.

•

alcohol pad

•

gauze pad

How to use your SOGROYA Pen

5 steps you should follow for a SOGROYA injection:

Step 1: Prepare your SOGROYA Pen

Step 2: Check the SOGROYA flow with each new Pen

Step 3: Select your dose

Step 4: Inject your dose

Step 5: After your injection

For further information about your Pen see: Frequently Asked Questions and Important information

Important information

 

Pay special attention to these notes as they are important for safe use of the Pen.

Additional information

SOGROYA is a prefilled growth hormone Pen. It contains 15 mg of somapacitan-beco and delivers doses from 0.1 mg to 8.0 mg, in increments of 0.1 mg. SOGROYA is for use under the skin only (subcutaneous) for injection 1 time each week.

Do not share your SOGROYA Pen and needles with another person. You may give another person an infection or get an infection from them.

Do not use your Pen without proper training from your healthcare provider. Make sure that you are confident in giving an injection with the Pen before you start your treatment. If you are blind or have poor eyesight and cannot read the dose counter on the Pen, do not use this Pen without help. Get help from a person with good eyesight who is trained to use the Pen.

Step 1. Prepare your SOGROYA Pen

•

Wash your hands with soap and water.

•

Check the name, strength, and colored label on your Pen to make sure that it contains SOGROYA in the right strength.

•

Pull off the Pen cap.

•

Turn the Pen upside down 1 or 2 times to check that the SOGROYA in your Pen is clear to almost clear and colorless to slightly yellow (See Figure A). If SOGROYA looks cloudy or you see particles, do not use the Pen.

•

When you are ready to give your injection, get a new disposable needle, and remove the paper tab.

•

Push the needle straight onto the Pen. Turn the needle clockwise until it is on tight (See Figure B).

Make sure the right pen is used. Especially if you use more than one type of injection medicine. Using the wrong medicine could be harmful to your health.

Always use a new needle for each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

•

Pull off the outer needle cap and throw it away (dispose of) (See Figure C).

•

Pull off the inner needle cap and throw it away (dispose of) (See Figure D).

A drop of SOGROYA may appear at the needle tip. This is normal, but you must still check the SOGROYA flow with each new Pen (See Step 2).

Never use a bent or damaged needle.

Step 2. Check the SOGROYA flow with each new Pen

If your Pen is already in use, go to Step 3.

•

Before using a new Pen, check the SOGROYA flow to make sure the growth hormone can flow through the Pen and needle.

•

Turn the dose selector clockwise 1 marking on the dose counter to select 0.1 mg. You may hear a faint “click” when you turn the dose selector (See Figure E).

•

1 marking on the dose counter equals 0.1 mg (See Figure F).

•

Hold the Pen with the needle pointing up. Press and hold in the dose button until the dose counter returns to “0”. The “0” must line up with the dose pointer (See Figure G).

•

Check that a drop of SOGROYA appears at the needle tip (See Figure H).

If no SOGROYA appears, repeat Step 2 up to 6 times.

If you still do not see a drop of SOGROYA, change the needle:

•

Carefully remove the needle from the Pen by turning the needle counterclockwise. Place the needle in a sharps disposal container immediately (See Step 5).

•

Repeat Step 2 again.

Do not use the Pen if a drop of SOGROYA still does not appear after changing the needle and repeating Step 2. Call Novo Nordisk at 1-888-668-6444 for help.

Step 3. Select your dose

•

To start, check that the dose pointer is set at “0”.

•

Turn the dose selector clockwise to select the dose you need (See Figure I). When you have selected your dose, you can go to Step 4.

If there is not enough SOGROYA left to select a full dose, see Frequently Asked Questions.

The dose counter shows the dose in “mg” (See Figure J and Figure K). Always use the dose counter to select the exact dose. Do not use the “click” sounds you hear when you turn the dose selector to select your dose. Only the dose pointer on the dose counter will show the exact dose selected.

If you select the wrong dose, you can turn the dose selector clockwise or counterclockwise to the correct dose (See Figure L).

The Pen “clicks” sound and feel differently when the dose selector is turned clockwise, counterclockwise, or if you forcefully move it past the number of “mg” left in the Pen.

Step 4. Inject your dose

•

Select the injection site.

•

SOGROYA can be injected under the skin (subcutaneously) of your stomach area (abdomen), upper arms, upper legs (thighs) or buttocks as instructed by your healthcare provider (See Figure M). Change the injection site every week.

•

Wipe the injection site with an alcohol pad and let the area dry.

•

Insert the needle into your skin as your healthcare provider has shown you (See Figure N).

•

Make sure you can see the dose counter. Do not cover it with your fingers. This could block the injection.

•

Press and hold down the dose button until the dose counter shows “0” (See Figure O). The “0” must line up with the dose pointer. You may then hear or feel a “click”.

•

Continue to hold down the dose button with the needle in your skin.

If “0” does not appear in the dose counter after continuously pressing the dose button, your needle may be blocked or damaged. See Frequently Asked Questions.

•

Keep holding down the dose button with the needle in your skin and slowly count to 6 to make sure that the full dose has been delivered (See Figure P).

•

Carefully remove the needle from your skin (See Figure Q). If blood appears at the injection site, press lightly with a gauze pad. Do not rub the area.

You may see a drop of SOGROYA at the needle tip after injecting. This is normal and does not affect your dose.

Step 5. After your injection

•

Carefully remove the needle from the Pen by turning the needle counterclockwise (See Figure R).

•

Place the needle in an FDA-cleared sharps disposal container immediately to reduce the risk of a needle stick (See Figure R).

Always throw away (dispose of) the needle after each injection.

For further information about safe sharps disposal, see Frequently Asked Questions.

•

Put the Pen cap on your Pen after each use to protect SOGROYA from direct light (See Figure S). See “How should I store my SOGROYA Pen?”.

Do not try to put the needle cap back on. You may stick yourself with the needle.

Always remove the needle from your Pen immediately after each injection. This reduces the risk of contamination, infection, leakage of SOGROYA, and blocked needles leading to incorrect dosing.

How should I store my SOGROYA Pen?

Before you use SOGROYA Pen for the first time:

•

Store your new, unused SOGROYA Pen in a refrigerator between 36°F to 46°F (2°C to 8°C).

•

Store your new, unused SOGROYA Pen with the cap on and in the original carton.

•

Do not freeze SOGROYA.

•

When stored in the refrigerator, do not store the SOGROYA Pen directly next to the cooling element.

•

Keep SOGROYA away from direct heat and light.

•

Do not use SOGROYA if it has been frozen or in temperatures warmer than 86ºF (30°C).

•

Do not use SOGROYA after the expiration date printed on the carton and the Pen.

After you use SOGROYA Pen and there is still medicine left:

•

Store remaining SOGROYA in the refrigerator between 36°F to 46°F (2°C to 8°C) and use within 6 weeks.

•

Store your in-use SOGROYA Pen with the cap on and keep it in the original carton.

Do not store SOGROYA Pen with the needle attached.

If needed, unused and in-use SOGROYA pens can be stored out of the refrigerator. SOGROYA pens can be stored at room temperature no warmer than 77ºF (25ºC) for up to 3 days (72 hours) and then returned to the refrigerator. Throw away (dispose of) SOGROYA if it has been stored above 77°F (25°C) for more than 3 days (72 hours) or in temperatures warmer than 86°F (30°C).

Always keep your SOGROYA Pen and needles out of reach of others, especially children.

Frequently Asked Questions

How do I see how much SOGROYA is left in my Pen?

The Pen scale shows you approximately how much SOGROYA is left in your Pen (See Figure T).

To see how much SOGROYA is left in your Pen, use the dose counter:

Turn the dose selector clockwise until the dose counter stops. The dose pointer will line up with the number of “mg” left in the Pen. You can select a maximum dose of 8.0 mg. If the dose counter stops with the dose pointer lined up with “8”, at least 8.0 mg are left in your Pen.

If the dose counter stops with the dose pointer lined up with “4.8”, only 4.8 mg are left in your Pen (See Figure U).

What if I need a larger dose than what is left in my Pen?

It is not possible to select a larger dose on the dose counter than the number of “mg” left in your Pen. If you need more SOGROYA than you have left in your Pen, you can use a new Pen or split your dose between your current Pen and a new Pen. Only split your dose if you have been trained or advised by your healthcare provider on how to do this. You may find it helpful to use a calculator to plan the doses as instructed by your healthcare provider.

Be very careful to calculate your split dose correctly so that you do not give the wrong dose. If you are not sure how to split your dose using 2 Pens, then select and inject the dose you need with a new Pen.

What if no SOGROYA appears when I check the flow?

A. Your needle may be blocked or damaged, if no SOGROYA appears at the needle tip. Remove the needle as described in Step 5 and repeat Step 1 and Step 2.

B. Your Pen may be defective, if SOGROYA still does not appear after changing the needle. Do not use the Pen. Contact Novo Nordisk at 1-888-668-6444.

What if “0” does not appear after completing my injection?

The needle may be blocked or damaged, and you have not received any SOGROYA, even though the dose counter has moved from the dose that you have set. Remove the needle as described in Step 5 and repeat Step 1 to Step 4.

How should I take care of my Pen?

Be careful not to drop your Pen or knock it against hard surfaces. Do not expose your Pen to dust, dirt, liquid, or direct light. See “How should I store SOGROYA?” Do not try to refill your Pen, it is prefilled.

What if I drop my Pen?

If you drop your Pen or think that something is wrong with it, attach a new disposable needle and check the SOGROYA flow before you inject (See Step 1 and Step 2). Do not try to repair your Pen or pull it apart.

How do I clean my Pen?

Do not wash, soak, or lubricate your Pen. If necessary, clean it with mild detergent on a moistened cloth.

Frequently Asked Questions

How do I throw away (dispose of) used SOGROYA needles and Pens?

Put your used needles and Pens in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and Pens in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:

•

made of a heavy-duty plastic,

•

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

•

upright and stable during use,

•

leak-resistant, and

•

properly labeled to warn of hazardous waste inside the container.

When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should dispose of used needles and Pens. For more information about safe sharps disposal, and for specific information about safe sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.

Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Important information

•

Caregivers must be very careful when handling needles to reduce the risk of needle sticks and infection.

www.sogroya.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

PATENT Information: http://novonordisk-us.com/products/product-patents.html

SOGROYA® is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk® is a registered trademark of Novo Nordisk A/S.

© 2004-2023 Novo Nordisk Health Care AG

For further information contact:

Novo Nordisk Inc.

800 Scudders Mill Road

Plainsboro, NJ 08536, USA

1-888-668-6444

Sogroya.com

Manufactured by:

Novo Nordisk Inc.

Plainsboro, NJ 08536

U.S. License No. 1261

Issued: 4/2023

Version: 1

 

Sogroya® 5 mg pen NDC 0169-2035-11

 

(somapacitan-beco) injection List: 203511

5 mg / 1.5 mL (3.3 mg/mL) Prefilled Pen

For subcutaneous Use Only

1x1.5 mL single-patient use prefilled pen

Dials in 0.025 mg increments and contains 5 mg total

Rx only

once weekly

 

Sogroya® 10 mg pen NDC 0169-2030-11

 

(somapacitan-beco) injection List: 203011

10 mg / 1.5 mL (6.7 mg/mL) Prefilled Pen

For subcutaneous Use Only

1x1.5 mL single-patient use prefilled pen

Dials in 0.05 mg increments and contains 10 mg total

Rx only

once weekly

 

Sogroya® 15 mg pen NDC 0169-2037-11

 

(somapacitan-beco) injection List: 203711

15 mg / 1.5 mL (10 mg/mL) Prefilled Pen

For subcutaneous Use Only

1x1.5 mL single-patient use prefilled pen

Dials in 0.1 mg increments and contains 15 mg total

Rx only

once weekly